RegeneRx Biopharmaceuticals (RGRX) Stock Price, News & Analysis

Company Overview

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for tissue repair and regeneration. The company’s work centers on Thymosin Beta 4 (Tβ4), a naturally occurring peptide that plays a key role in cellular migration, angiogenesis and wound healing. RegeneRx leverages its Tβ4 platform to advance treatments for a range of acute and chronic conditions in ophthalmology, dermatology, cardiology and neurology.

The company’s lead therapeutic candidate, RGN-259, is a topical formulation of Tβ4 that has been studied in clinical trials for dry eye syndrome and various dermatological indications, including epidermolysis bullosa. Additional pipeline candidates include RGN-352, an injectable form of Tβ4 for myocardial infarction and ischemic injury, and RGN-3479 for central nervous system repair. RegeneRx also explores complementary peptides for applications in inflammation, fibrosis and tissue remodeling.

Founded in 1995 and headquartered in Rockville, Maryland, RegeneRx has built a foundation of intellectual property around its Tβ4 platform, with worldwide patents and patent applications. The company has collaborated with academic institutions such as the University of Pittsburgh and formed strategic partnerships in Asia to support preclinical research and clinical development. These alliances aim to accelerate regulatory filings and eventual commercialization in key markets across North America, Europe and Asia.

Under the leadership of President and Chief Executive Officer Patrick C. Harned, RegeneRx’s management team includes professionals with extensive experience in drug development, regulatory affairs and corporate strategy. The board of directors brings additional expertise from the biotechnology and pharmaceutical industries, guiding the company’s efforts to translate its peptide-based science into meaningful therapies for patients worldwide.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.07
• Volume: N/A
• Average Volume: 19 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGRX Stock Analysis - Frequently Asked Questions

How have RGRX shares performed this year?

RegeneRx Biopharmaceuticals' stock was trading at $0.0014 at the beginning of the year. Since then, RGRX shares have decreased by 85.7% and is now trading at $0.0002.

When did RegeneRx Biopharmaceuticals' stock split?

Shares of RegeneRx Biopharmaceuticals reverse split before market open on Monday, August 14th 2023.The 1-100 reverse split was announced on Monday, August 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RegeneRx Biopharmaceuticals investors own include Fulcrum Therapeutics (FULC), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Biocept (BIOC) and Onconova Therapeutics (ONTX).

Company Calendar

• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:RGRX
• Previous Symbol: OTC:RGRX
• CIK: 707511
• Web: www.regenerx.com
• Phone: (301) 208-9191
• Fax: 301-280-1996
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 2.98